Morgan Stanley Maintains Equal-Weight on TransMedics Gr, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Cecilia Furlong has maintained an Equal-Weight rating on TransMedics Group (NASDAQ:TMDX) and increased the price target from $54 to $75.
December 04, 2023 | 6:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on TransMedics Group but raised the price target from $54 to $75, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Morgan Stanley suggests a positive sentiment towards TransMedics Group's future performance. This could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100